EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer

Min-Chi Cheng iD, Po-Huang Chen iD, Yu-Guang Chen, Shiue-Wei Lai iD, Jia-Hong Chen, Ming-Shen Dai iD, Ping-Ying Chang

Life · 30.03.2026 · 16 (4) · 564

DOI: 10.3390/life16040564 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life, online erschienen am 30.03.2026. Verfasst von Min-Chi Cheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei 114, …. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tri-Service General Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal sequencing of regorafenib and trifluridine/tipiracil (FTD/TPI) in refractory metastatic colorectal cancer (mCRC) remains uncertain, particularly in Asian populations.

Methods

We retrospectively analyzed 110 patients with mCRC who sequentially received both agents between 2011 and 2025. Patients were categorized into regorafenib followed by FTD/TPI (Rego → FTD/TPI, n = 88) and FTD/TPI followed by regorafenib (FTD/TPI → Rego, n = 22). Co-primary endpoints were time to treatment discontinuation (TTD) and overall survival (OS). Propensity score-based weighting methods, including stabilized inverse probability of treatment weighting (primary analysis), were used to adjust for baseline imbalances. Multivariable Cox regression was performed as a sensitivity analysis.

Results

No statistically significant differences were observed between treatment sequences. In the primary analysis, the hazard ratio (HR) for TTD was 1.01 (95% CI 0.71–1.43), and for OS was 1.19 (95% CI 0.67–2.12), with FTD/TPI → Rego as reference. Median TTD was 6.8 versus 8.9 months, and median OS was 14.6 versus 20.2 months, respectively.

Conclusions

Clinical outcomes were comparable regardless of treatment order, supporting individualized sequencing decisions in refractory mCRC.

Schlagwörter

Stichwörter der Autor:innen

inverse probability of treatment weightingmetastatic colorectal cancerpropensity scoreregorafenibtreatment sequencingtrifluridine/tipiracil

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei 114, Taiwan.
  • Department of Oncology, Tri-Service General Hospital, National Defense Medical University, Taipei 114, Taiwan.

ORCID-Profile: Min-Chi Cheng, Po-Huang Chen, Shiue-Wei Lai, Ming-Shen Dai

Förderung

  • Tri-Service General Hospital

Zitieren

APA

Cheng, M. C., Chen, P. H., Chen, Y. G., Lai, S. W., Chen, J. H., Dai, M. S., & Chang, P. Y. (2026). Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer. Life, 16(4), 564. https://doi.org/10.3390/life16040564

Vancouver

Cheng MC, Chen PH, Chen YG, Lai SW, Chen JH, Dai MS, et al. Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer. Life. 2026;16(4):564. doi:10.3390/life16040564

BibTeX
@article{Cheng2026,
  author = {Cheng, Min-Chi and Chen, Po-Huang and Chen, Yu-Guang and Lai, Shiue-Wei and Chen, Jia-Hong and Dai, Ming-Shen and Chang, Ping-Ying},
  title = {Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer},
  journal = {Life},
  year = {2026},
  volume = {16},
  number = {4},
  pages = {564},
  doi = {10.3390/life16040564}
}
Kostenlos starten →